ConductScience.org, home

Library / Trials

The Role of Environmental Temperatures in Respiratory Control

NCT07470086, Not applicable, Not yet recruiting, Indiana University

Trial 10

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

FieldValueSource
TitleThe Role of Environmental Temperatures in Respiratory ControlClinicalTrials.gov
NCT numberNCT07470086ClinicalTrials.gov
StatusNot yet recruitingClinicalTrials.gov
PhasesNot applicableClinicalTrials.gov
Enrollment15 participants, estimatedClinicalTrials.gov
Lead sponsorIndiana UniversityClinicalTrials.gov
ConditionsWork of BreathingClinicalTrials.gov
InterventionsThermoneutral temperature environment, Cold temperature environment, Hot temperature environmentClinicalTrials.gov
First posted2026-03-13ClinicalTrials.gov
Last updated2026-03-13ClinicalTrials.gov

Registered outcomes 12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescriptionSource
PrimaryChange in Stroop Color-Word Test Time PerformanceBefore and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)Time performance on the Stroop Color-Word Test (min:sec) will be measured every 45 minutes during each experimental breathing task.ClinicalTrials.gov
PrimaryChange in Stroop Color-Word Test Error PerformanceBefore and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)The number of errors on the Stroop Color-Word Test will be measured every 45 minutes each experimental breathing task.ClinicalTrials.gov
PrimaryChange in Perception of Dyspnea IntensityBefore and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)
Participants will rate perception of dyspnea (breathing) intensity on a visual analog scale (VAS) every 45 minutes during each breathing task. The participant will draw a vertical marker line on a horizontal line (100mm), indicating their breathing perception from "not noticeable" (0mm) to "maximal imaginable intensity" (100mm).
ClinicalTrials.gov
PrimaryChange in Perception of Dyspnea UnpleasantnessBefore and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)
Participants will rate perception of dyspnea (breathing) unpleasantness on a visual analog scale (VAS) every 45 minutes during each breathing task. The participant will draw a vertical marker line on a horizontal line(100mm), indicating their breathing perception from "not unpleasant"(0mm) to "maximal imaginable unpleasantness" (100mm).
ClinicalTrials.gov
SecondaryChange in Diaphragm ThicknessBefore and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)
Diaphragm thickness will be measured via Doppler ultrasound of the10th/11th rib space during functional residual capacity (FRC; rest) and end-inspiration, as well as during the maximal inspiratory pressure (MIP)test from FRC before and after each condition.
ClinicalTrials.gov
SecondaryChange in Heart Rate VariabilityBefore and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)Heart rate variability (beats per minute) will be measured continuously during each breathing task via 3-lead electrocardiograph (ECG).ClinicalTrials.gov
SecondaryChange in Peripheral Oxygen SaturationBefore and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)Peripheral oxygen saturation will be measured continuously during each breathing task via pulse oximetry.ClinicalTrials.gov
SecondaryChange in Blood Pressure - Brachial ArteryBefore and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)Blood pressure will be measured every 10 minutes during each breathing task via a standard blood pressure cuff and auscultation of the brachial artery.ClinicalTrials.gov
SecondaryChange in Blood Pressure - Finger PhotoplethysmographyBefore and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)Blood pressure will be measured continuously during each breathing task via finger photoplethysmography.ClinicalTrials.gov
SecondaryChange in Heart RateBefore and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)Heart Rate will be measured continuously during each breathing task by 3-lead electrocardiograph (ECG).ClinicalTrials.gov
SecondaryChange in Cerebral Blood Oxygen KineticsBefore and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)Oxyhemoglobin and deoxyhemoglobin (uptake/extraction, uM) will be measured continuously via near-infrared spectroscopy (NIRS) of the pre-frontal cortex during each breathing task.ClinicalTrials.gov
SecondaryChange in Cerebral Blood VelocityBefore and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)
Bilateral transcranial Doppler Ultrasound will be used to continuously measure middle and posterior cerebral artery blood velocity during each breathing task. The ultrasound transducers will be placed on both sides of the head at the temporal windows and the positions will be fixed using a transducer holder.
ClinicalTrials.gov

Outcomes 0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured asSource

Results by group 0

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnitsSource

Participant flow 0

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits countedSource

Adverse events 0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEventsSource

Adverse event totals 0

The totals the trial posted for each group.

TotalGroupAffectedAt riskSource

Papers 0

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource

Grants 0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

ProjectTitlePrincipal investigatorsOrganizationFunderFiscal yearsSource

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource

Tests 1

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

TestNamed asSource
Stroop Color-Word TestPrimary outcomeConductCognition

Source 5

FieldValueSource
Releasetrials-2026-11-12-0.4.0ClinicalTrials.gov
Release manifest SHA-2560f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4ClinicalTrials.gov
Registry capture2026-11-12ClinicalTrials.gov
Results copy, AACT2026-03-23ClinicalTrials.gov
NIH clinical studies file2026-11-13ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)